Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia CorpfiledCriticalPharmacia Corp
Publication of AR026747A1publicationCriticalpatent/AR026747A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Una forma cristalina novedosa (Forma L) de la droga eplerenona antagonista del receptor de la aldosterona con una estabilidad física relativamente alta atemperaturas normales de almacenamiento y uso. Ser proporcionan composiciones farmacéuticas que i ncluyen la eplerenona de Forma L, opcionalmente acompanada poruna o más de otras formas en estado solido de eplerenona, en una cantidad total de dosaje unitario de eplerenona de entre aproximadamente 10 y aproximadamente1000 mg, y que además incluyen uno o más excipientes aceptables para uso farmacéutico. Se proporcionan procesos para preparar eplerenona de Forma L y paraagregar composiciones que incluyen a la eperenona de Forma L. También se proporciona un método para la profilaxis y/o el trat amiento de una condicion otrastorno mediados por la aldosterona, que incluye administrar a un sujeto una cantidad de eplerenona eficaz en términos terapéuticos, donde por lo menos unafraccion de la eplerenona es eplerenona de Forma L.A novel crystalline form (Form L) of the drug eplerenone antagonist of the aldosterone receptor with relatively high physical stability at normal storage and use temperatures. Ser provide pharmaceutical compositions that include Form L eplerenone, optionally accompanied by one or more other forms in the solid state of eplerenone, in a total unit dosage amount of eplerenone of between about 10 and about 1000 mg, and which also include one or more more excipients acceptable for pharmaceutical use. Processes are provided to prepare Form L eplerenone and to aggregate compositions that include Form L eperenone. A method is also provided for the prophylaxis and / or treatment of a condition other condition mediated by aldosterone, which includes administering to a subject. an amount of eplerenone effective in therapeutic terms, where at least one fraction of eplerenone is Form L eplerenone.
ARP000106471A1999-12-082000-12-06
EPERENONA CRYSTAL FORM
AR026747A1
(en)
PHARMACEUTICAL COMPOSITION, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PROPHYLAXIS OF A CONDITION MEDIATED BY ALDOSTERONE AND THE PROCESS FOR ITS PREPARATION.
ACTIVATING COMPOUNDS OF hPPARGAMMA AND hPPARALFA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD FOR THE TREATMENT AND / OR PREVENTION OF A DISEASE MEDIATED BY THE SAME, AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
USE OF A COMBINATION OF ORGANIC THERAPEUTIC COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, A THERAPEUTIC AGENT, AND A PHARMACEUTICAL COMPOSITION
3- (1-METHYL-3-INDOLIL) -4- (1-METHYL-6-NITRO-3-INDOLIL) -1H-PIRROL-2,5-DIONA, AMORPHALLY, PROCESSES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT THE UNDERSTAND AND USE OF SUCH COMPOUND IN THE MANUFACTURE OF MEDICINES
Use of at least one compound selected from melatonin, melatoninergic agents, melatonin agonists and antagonists, in an amount of 0.0025-50 mg, to prepare a useful medicine for the treatment and improvement of the restorative quality of sleep.